What Would US FDA Do If Supreme Court Eliminates Or Curtails Chevron Deference?
Executive Summary
Lawyers say agency will have to bolster its administrative record as judges tackle complex policy and scientific issues previously left to FDA. Some cases, such as challenges to exclusivity decisions, may be reopened.
You may also be interested in...
GenBioPro Mifepristone Ruling Intensifies Tension Between Courts
West Virginia judge finds GenBioPro has standing to sue state and that Comstock Act does not prohibit mailing of medication abortion drugs. Ruling deepens conflict between courts as Fifth Circuit hears appeal of Texas district court order staying approval of mifepristone.
Judge Jackson’s Patent, FDA Rulings Show She Is ‘Super Smart’ And Would Be Beneficial For Pharma
Supreme Court nominee issued three decisions on Hatch-Waxman regime as district court judge, including case in which she ruled against the FDA’s denial of orphan drug designation and another in which she deferred to the agency’s view on exclusivity. Her analysis of facts may play a role if the court takes up a case on administrative agency deference.
Pediatric Exclusivity: Court Backs US On When Studies 'Fairly Respond' To Requests
However, FDA must explain why denial of Sensipar's pediatric exclusivity was consistent with exclusivity award for J&J's Ortho Tri-Cyclen, US judge says. In swipe at plaintiff Amgen, court says pediatric study reports themselves guide exclusivity determinations, not the amount of effort a sponsor puts into those studies.